Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022Business Wire • 07/27/22
Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588Business Wire • 07/27/22
Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus InfectionsBusiness Wire • 06/21/22
Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic DiseasesBusiness Wire • 05/12/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTXPRNewsWire • 04/25/22
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Cortexyme, Inc. Investors With Losses to Inquire About Securities Class Action Investigation – CRTXBusiness Wire • 04/05/22
CRTX INVESTOR ALERT: Hagens Berman, National Trial Attorneys, Investigating Cortexyme, Inc. (CRTX) For Possible Securities Law Violations, Encourages Investors With Significant Losses to Contact FirmNewsfile Corp • 03/23/22
CRTX SHAREHOLDER ALERT: ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Cortexyme, Inc. Investors with Losses to Inquire About Securities Class Action Investigation - CRTXNewsfile Corp • 03/21/22
Cortexyme, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the FirmNewsfile Corp • 03/21/22
Cortexyme Provides New GAIN Trial Data at AD/PD 2022 Demonstrating Potential Benefit of Lysine Gingipain Inhibition in Mild to Moderate Alzheimer's PopulationBusiness Wire • 03/21/22
ROSEN, A LEADING LAW FIRM, Encourages Cortexyme, Inc. Investors With Losses to Inquire About Securities Class Action Investigation - CRTXPRNewsWire • 03/16/22
Cortexyme Announces Preclinical Data Highlighting Potential Therapeutic Benefits of Atuzaginstat for the Treatment of High-Risk Oral Potentially Malignant DisordersBusiness Wire • 03/09/22
Cortexyme Reports Safety and Pharmacokinetics Results from Single Ascending Dose Portion of its Phase 1 Clinical Trial of COR588Business Wire • 03/08/22
CRTX INVESTOR NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Cortexyme, Inc. Investors with Losses to Inquire About Securities Class Action Investigation - CRTXNewsfile Corp • 03/06/22
ROSEN, A TOP RANKED LAW FIRM, Encourages Cortexyme, Inc. Investors with Losses to Inquire About Securities Class Action Investigation - CRTXNewsfile Corp • 03/01/22
CORTEXYME ALERT: Bragar Eagel & Squire, P.C. is Investigating Cortexyme, Inc. on Behalf of Cortexyme Stockholders and Encourages Investors to Contact the FirmBusiness Wire • 02/25/22